Biocon Limited announced on 24 May 2024 that it signed an exclusive licensing and supply agreement with Korea’s Handok Inc for the commercialisation in South Korea of its synthetic liraglutide, biosimilar to Novo Nordisk’s Victoza®.
Under the terms of the agreement, Biocon will be responsible for the development, manufacturing and supply of the drug product, and Handok will manage regulatory approvals and commercialisation in the South Korean market.
Biocon’s liraglutide became the first approved biosimilar to Novo Nordisk’s Victoza® in the UK in March 2024.